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Abstract
Background: vaccinations for COVID-19 have been prioritised for older people living in care homes. However, vaccination
trials included limited numbers of older people.
Aim: we aimed to study infection rates of SARS-CoV-2 for older care home residents following vaccination and identify
factors associated with increased risk of infection.
Study Design and Setting: we conducted an observational data-linkage study including 14,104 vaccinated older care home
residents in Wales (UK) using anonymised electronic health records and administrative data.
Methods: we used Cox proportional hazards models to estimate hazard ratios (HRs) for the risk of testing positive for SARS-
CoV-2 infection following vaccination, after landmark times of either 7 or 21 days post-vaccination. We adjusted HRs for
age, sex, frailty, prior SARS-CoV-2 infections and vaccination type.
Results: we observed a small proportion of care home residents with positive polymerase chain reaction (tests following
vaccination 1.05% (N = 148), with 90% of infections occurring within 28 days. For the 7-day landmark analysis we found a
reduced risk of SARS-CoV-2 infection for vaccinated individuals who had a previous infection; HR (95% confidence interval)
0.54 (0.30, 0.95). For the 21-day landmark analysis, we observed high HRs for individuals with low and intermediate frailty
compared with those without; 4.59 (1.23, 17.12) and 4.85 (1.68, 14.04), respectively.
Conclusions: increased risk of infection after 21 days was associated with frailty. We found most infections occurred within
28 days of vaccination, suggesting extra precautions to reduce transmission risk should be taken in this time frame.
Keywords: COVID-19, SARS-CoV-2, vaccination, care homes, older people
Key Points
• Increased risk of infection after 21 days was associated with frailty.
• Most (90%) positive PCR tests occurred within 28 days of vaccination.
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Introduction
Vaccinations for SARS-CoV-2 in the UK have been priori-
tised to older people living in care homes [1, 2]. However,
the efficacy of the COVID-19 vaccine in older people is
relatively unknown, with very few trials recruiting older
people and older people with frailty [3]. Specifically, the
Oxford–AstraZeneca vaccine trials had less than 4% of par-
ticipants over 70 years of age and those with comorbidities
were a minority [4]. Similarly, the initial Pfizer BioNTECH
trials included only 774 individuals aged 75 or over and
3,848 individuals aged 65 and over from a total of 18,198
vaccinated individuals [5].
Care homes are a keystone of adult social care. They
provide accommodation and care for those needing substan-
tial help with personal care, but more than that, they are
people’s homes [6, 7]. In 2016, there were 11,300 care homes
in the UK, with a total of 410,000 residents [8]. Within
care homes, people live in proximity and may live with
frailty and many different health conditions, making them
susceptible to outbreaks of infectious disease [6]. COVID-19
is described by Lithande et al. [9], as ‘ . . . a dynamic, specific
and real threat to the health and well-being of older people’
(2020, p. 10). The impacts of COVID-19 on this sub-
population have been reported widely in both international
and UK media, and in a growing peer reviewed literature.
Here, we produced a rapid report, in near real-time, on
the risk of SARS-CoV-2 infection for vaccinated care home
residents. This is the first study we are aware of investigating
this vulnerable sub-population. Furthermore, we included
information on previous positive SARS-CoV-2 polymerase
chain reaction (PCR) tests, age, sex and frailty. We were able
to do this using the existing infrastructure and linked data
from the Secure Anonymised Information Linkage (SAIL)
Databank [10–12].
Methods
Study design and setting
We conducted an observational data-linkage study for older
care home residents in Wales (UK). We used data on 14,104
individuals receiving a SARS-CoV-2 vaccination from 4
December 2020 to 12 February 2021 and testing data from
4 December 2020 to 4 March 2021 to investigate positive
SARS-CoV-2 PCR tests following a vaccination.
Data sources
We used linked longitudinal data from the SAIL Databank to
create our datasets [10–12]. Specifically, we used the COVID
Vaccine Dataset (CVD) to identify individuals living in care
homes who had received a vaccination. We included all
individuals identified as an ‘older adult resident in a care
home’. The Pathology COVID-19 Daily data was used to
identify dates of positive SARS-CoV-2 PCR tests. A cleaned
and pre-linked version of the Welsh Demographic Service
Dataset was used to determine demographic information for
each individual [13]. We also linked to the Patient Episode
Database for Wales (PEDW) to include an indication of
frailty.
Hospital frailty risk score
The Hospital Frailty Risk Score (HFRS) was developed using
Hospital Episode Statistics (HES), a database containing
details of all admissions, emergency department attendances
and outpatient appointments at NHS hospitals in England,
and validated on over one million older people using hos-
pitals in 2014/15 [14]. The HFRS uses the International
Classification of Disease version 10 (ICD-10) [15] codes to
search for specific conditions from secondary care. A weight
is then applied to the conditions and a cumulative sum is
used to determine a frailty status of low, intermediate or high.
We additionally included a HFRS score of ‘No score’ for
people who had not been admitted to hospital in the look
back period. We calculated the HFRS using the PEDW, the
Welsh counterpart to HES, on the vaccination date, with
a two year look back of all hospital admissions recorded in
Wales.
Variables
Our outcome of interest was the time to a positive SARS-
CoV-2 PCR test following a vaccination. Individuals
were censored for death or the end of study period. We
included covariates for previous positive SARS-CoV-2 PCR
tests (yes/no), age (continuous), sex (male/female), frailty
(HFRS: no score, low, intermediate, high), and vaccine
manufacturer (Oxford–AstraZeneca, Pfizer-BioNTECH).
Previous positive SARS-CoV-2 PCR tests were identified at
any time point before vaccination.
Statistical methods
We included basic demographic information and investi-
gated differences between individuals who had a positive
SARS-CoV-2 PCR test following vaccination. We produced
a Kaplan–Meier survival curve and an empirical cumulative
distribution function (CDF) for the time to first positive
SARS-CoV-2 PCR test following vaccination. We also calcu-
lated hazard ratios (HR) for our covariates using univariable
and multivariable Cox proportional hazards models. For the
Cox proportional hazards models, we defined two landmark
periods for immunisation, 7 and 21 days. In a landmark
analysis, only those who have not had an event (positive
PCR test) for the specified time period are included. In other
words, individuals who had a positive SARS-CoV-2 PCR
test within the 7 and 21-day periods were removed from the
respective analyses, see Figure 3 for an example. We included
these periods as a proxy for the varying number of days for
the vaccine to become effective. As a sensitivity analysis, we
repeated the analysis with the 7 and 21-day immunisation
(landmark) periods, but applied a maximum follow-up of
14 days. Individuals were right censored for death or the end
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Table 1. Demographic information for the total cohort and the cohort stratified by those who had a subsequent positive
SARS-CoV-2 PCR test following vaccination
Positive PCR test post-vaccine
Total No Yes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
N 14,104 13,956 (98.95%) 148 (1.05%)
Previous COVID infection 2,868 (20.3%) 2,848 (20.4%) 20 (13.5%)
Mean age (SD) 85 (8.3) 85.1 (8.3) 84.5 (8.4)
Sex
Male 4,096 (29.0%) 4,045 (29.0%) 51 (34.5%)
Female 10,008 (71.0%) 9,911 (71.0%) 97 (65.5%)
HFRS
No Score 6,409 (45.4%) 6,356 (45.5%) 53 (35.8%)
Low 1,149 (8.1%) 1,138 (8.2%) 11 (7.4%)
Intermediate 3,009 (21.3%) 2,969 (21.3%) 40 (27%)
High 3,537 (25.1%) 3,493 (25.0%) 44 (29.7%)
Vaccine Type
Oxford–Astrazeneca 12,571 (89.1%) 12,459 (89.3%) 112 (75.7%)
Pfizer-BioNTECH 1,533 (10.9%) 1,497 (10.7%) 36 (24.3%)
SD, Standard deviation
Figure 1. Kaplan–Meier curve for the time to the first positive SARS-COV-2 PCR test following vaccination.
the proportional hazards assumption were tested for using
Schoenfeld residuals.
Results
We identified 14,501 vaccinated older adult residents in a
care home in the CVD dataset. We removed 240 residents
prior to analysis because of incomplete demographic
information. We restricted the age group to those aged
60+, removing a further 157 individuals, resulting in
14,104 residents used for analysis. The basic demographic
information for the total cohort and the cohort stratified
by those who had a subsequent positive SARS-CoV-2 PCR
test following vaccine is presented in Table 1. Figure 1 shows
the Kaplan–Meier curve for the time to first positive PCR
test following vaccination. The curve indicates an overall
small proportion of individuals testing positive following
vaccination. Figure 2 shows the empirical CDF for the
times between first positive PCR test and vaccination.
The Kaplan–Meier curve and empirical CDF suggest a
susceptible period of vaccinated individuals up to 42 days,
with approximately 40% of individuals having a positive
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Figure 2. CDF for the time between vaccination and first positive PCR test (N = 148).
Figure 3. Immunisation (landmark) analysis timeline example.
21 days, 90% within 28 days and over 95% within
35 days.
HRs and 95% confidence intervals (CIs) for the Cox
proportional hazards models are presented in Tables 2
and 3. In our multivariable analyses, we found a reduced
risk of SARS-CoV-2 infection for vaccinated individuals
who had a previous infection after a 7-day immunisation
period; HR (95% CI) 0.54 (0.30, 0.95), and an increased
risk for those receiving the Pfizer-BioNTECH vaccine
HR 3.83 (2.45, 5.98). The 21-day immunisation period
multivariable model indicated frailty as a risk factor,
with low frailty having a HR of 4.59 (1.23, 17.12) and
intermediate frailty with a HR of 4.85 (1.68, 14.04).
The Schoenfeld residual test indicated only the 21-day
immunisation/14-day observation model deviated from
the proportional hazards assumption at the 95% level (P
value 0.04), all other models met proportional hazards
assumptions.
Discussion
Our study focussed on older adults resident in care homes.
This is a particularly vulnerable sub-population that has not
previously been studied in relation to infection rates for
SARS-CoV-2 following vaccination, and which has suffered
considerably from the most severe effects of the pandemic.
Our study used a large cohort of 14,104 individuals, which
is comparable to the entire case population of the ChA-
dOx1 nCoV-19 vaccine (N = 12,174) [4]. We were also able
to include information on frailty, previous infections and
vaccination received.
We found 148 (1.05%) of individuals in our cohort had a
positive PCR test following vaccination. The Kaplan–Meier
curve and empirical CDF suggest a susceptible period for
infection of up to 42 days, with approximately 99% of
infections occurring within this period. It is well known
that there is a delay following immunisation for the vaccine
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Table 2. Univariable and multivariable Cox proportional hazards models with 7 and 21-day landmark times applied to
the cohort. HRs and presented with 95% CIs. Results that are statistically significant at the 95% level are highlighted in
bold font
7-day landmark time 21-day landmark time
HRs (95% CI) Univariable Multivariable Univariable Multivariable
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 1.004 (0.98, 1.028) 1.01 (0.985, 1.036) 1.024 (0.976, 1.074) 1.031 (0.981, 1.084)
Previous positive PCR test (reference: no)
Yes 0.667 (0.379, 1.175) 0.535 (0.301, 0.949) 0.931 (0.353, 2.46) 0.807 (0.301, 2.159)
Sex (reference: female)
Male 1.39 (0.919, 2.104) 1.428 (0.929, 2.195) 1.246 (0.56, 2.773) 1.285 (0.563, 2.932)
HFRS (reference: no score)
Low 1.597 (0.791, 3.226) 1.605 (0.794, 3.244) 4.487 (1.205, 16.71) 4.585 (1.229, 17.12)
Intermediate 1.645 (0.996, 2.717) 1.767 (1.066, 2.927) 4.662 (1.62, 13.417) 4.852 (1.677, 14.04)
High 1.298 (0.777, 2.168) 1.374 (0.82, 2.303) 2.511 (0.797, 7.913) 2.574 (0.813, 8.15)
Vaccine (reference: Oxford–Astrazeneca)
Pfizer-BioNTECH 3.362 (2.166, 5.216) 3.829 (2.452, 5.979) 1.921 (0.727, 5.077) 2.196 (0.821, 5.873)
Observations 13,989 13,989 13,605 13,605
Events 97 97 27 27
Concordance (Standard Error) 0.669 (s.e. 0.028) 0.693 (s.e. 0.052)
Global Schoenfeld residual
Chi-squared 8.9 7.8
Degrees of freedom 7 7
P value 0.26 0.35
Table 3. Univariable and multivariable Cox proportional hazards models with 7 and 21-day landmark times applied to the
cohort and a maximum 14-day observation period. HRs and presented with 95% CIs. Results that are statistically significant
at the 95% level are highlighted in bold font
7-day landmark, 14-day observation 21-day landmark, 14-day observation
HRs (95% CI) Univariable Multivariable Univariable Multivariable
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 0.998 (0.97, 1.025) 1.005 (0.977, 1.034) 1.012 (0.963, 1.064) 1.014 (0.963, 1.068)
Previous positive PCR test (reference: no)
Yes 0.549 (0.273, 1.102) 0.435 (0.215, 0.881) 0.808 (0.276, 2.364) 0.693 (0.233, 2.055)
Sex (reference: female)
Male 1.526 (0.952, 2.446) 1.584 (0.969, 2.589) 1.025 (0.425, 2.471) 0.995 (0.402, 2.462)
HFRS (reference: no score)
Low 1.047 (0.438, 2.505) 1.04 (0.434, 2.49) 2.247 (0.436, 11.58) 2.307 (0.447, 11.911)
Intermediate 1.136 (0.631, 2.045) 1.226 (0.679, 2.216) 4.251 (1.453, 12.436) 4.479 (1.523, 13.169)
High 1.027 (0.576, 1.829) 1.095 (0.612, 1.958) 2.528 (0.802, 7.967) 2.653 (0.838, 8.401)
Vaccine (reference: Oxford–Astrazeneca)
Pfizer-BioNTECH 3.78 (2.307, 6.194) 4.316 (2.616, 7.121) 1.646 (0.563, 4.817) 1.917 (0.647, 5.682)
Observations 13,989 13,989 13,605 13,605
Events 73 73 24 24
Concordance (Standard Error) 0.684 (s.e. 0.032) 0.681 (s.e. 0.056)
Global Schoenfeld residual
Chi-squared 6.2 14.5
Degrees of freedom 7 7
P value 0.51 0.04
vigilance during this period for this highly vulnerable care
home population. For example, extra precautions should
be taken for visitations within care homes during this
period.
We found a large, and statistically significant reduced risk
for infection post-vaccine for individuals who had already
had a SARS-CoV-2 infection. The risk was approximately
halved, and those who had a prior infection may be more
robust and have existing antibodies, leading to a reduced risk
of subsequent infections. Increased levels of frailty, deter-
mined by the HFRS, were associated with substantially
increased risk of infection post-vaccine (up to almost 5-fold
increase for intermediate frailty in the 21-day landmark post-
vaccination). Frailty is complex, and those living with high
levels of frailty may need additional support. In particular,
increased care requires additional contact with carers, and
subsequently an increased risk of transmission of SARS-
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can be isolated. We note that the effect was not quite as
large in the highest frailty group. This simply may reflect
uncertainty in the risk estimates, or may be the result of more
complex management or identification of risk in this group.
In the 7-day landmark analysis, there was evidence to
suggest an increased risk of infection post-vaccination for
those receiving the Pfizer-BioNTECH vaccine compared
with the Oxford–AstraZeneca vaccine, but no statistically
significant difference in the 21-day landmark analysis. This
suggests the Oxford–AstraZeneca vaccine has a potentially
shorter time to become effective in our cohort.
Strengths
This analysis was possible using the existing infrastructure
of the SAIL Databank, and we will continue to investigate
adverse events for individuals receiving a vaccination. We
were able to rapidly develop and analyse a large cohort of
care home residents with the inclusion of individual level
information.
Limitations
Because of the nature of the vaccination rollout, we only had
a limited follow-up time and subsequently a small number
of events. At the time of analysis, we did not include infor-
mation of second doses because of very small numbers. We
will continue to monitor the care home population and will
update our analysis with an extended follow-up time and sec-
ond doses when possible. In further work, we aim to include
background prevalence of COVID-19 to help account for
the change in incidence over the study period. We also aim to
include multi-morbidities and additional measures of frailty
that do not rely on hospital data, such as the electronic frailty
index [16, 17], and we will investigate additional adverse
events such as mortality and hospitalisation.
Conclusion
Our findings suggest care home residents with frailty are the
most susceptible to infection post-vaccination and should be
prioritised for a second dose of the SARS-CoV-2 vaccine.
We also found a susceptible period of reinfection of up to 42
days, indicating extra care and precautions should be taken
in this period.
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